Compositions and methods related to inhibition of adenomas and adenocarcinomas
AssigneeThe Trustees of Columbia University in the City of New York
InventorsPiero D. Dalerba, Sara Viragova, Pierangela Palmerini
Life of this patent
Estimating the term…
Abstract
This application is directed to methods and compositions related to the treatment and diagnosis of adenocarcinomas, such as adenoid cystic carcinoma (ACC). The methods and compositions related to the use of CD49f, TP63, and/or KIT/CD117 cell-surface markers for subtyping the cancer cells. One method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to inhibit the differentiation of myoepithelial-like cells into ductal-like cells. Another method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to selectively reduce the viability of ductal-like cells.
Claims20
A method of reducing tumorigenicity and/or aggression of adenocarcinoma cells, the method comprising:
- administering a therapeutic agent that activates retinoic acid receptor and/or retinoid-X receptor signaling to the adenocarcinoma cells.
A method of reducing viability of adenocarcinoma cells, the method comprising:
- detecting the expression of at least one cell surface marker in the adenocarcinoma cells, wherein the at least one cell surface marker is selected from the group consisting of:
- CD49f, TP63, and KIT/CD117;
- and
- administering a therapeutic agent that inhibits retinoic acid receptor and/or retinoid-X receptor signaling to the adenocarcinoma cells,
- wherein the adenocarcinoma cells are administered the therapeutic agent that inhibits retinoic acid receptor and/or retinoid-X receptor signaling to upon detection of:
- less than 5% of the adenocarcinoma cells express TP63;
- more than 95% of the adenocarcinoma cells express KIT/CD117;
- or
- the adenocarcinoma cells have low expression of CD49f.
A method of reducing the size of a tumor, the method comprising:
- providing a tumor sample from a subject;
- detecting the expression of at least one cell-surface marker in the tumor sample, wherein the at least one cell surface marker is selected from the group consisting of:
- CD49f, TP63, and KIT/CD117;
- and
- administering a therapeutic agent that inhibits retinoic acid receptor and/or retinoid-X receptor signaling to the subject with a tumor sample comprising more than 95% of cells expressing KIT/CD117 or with a tumor sample comprising less than 5% of cells expressing TP63.
Dependencies are inferred from the claim text.